Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLD Study
2024-512884-30-00Phase 3Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Apr 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of pertuzumab, trastuzumab and docetaxel in breast cancer (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Invasive disease-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512884-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512884-30-00.